Cargando…

Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A

Detalles Bibliográficos
Autores principales:	Kowanetz, Marcin, Rabe, Christina, Xiao, Yuanyuan, Wu, Qun J, Koeppen, Hartmut, Leddy, Cecilia, Patel, Rajesh D, Powderly, John, Kohrt, Holbrook, Gettinger, Scott, Soria, Jean-Charles, Herbst, Roy S, Desai, Rupal, Denker, Mitchell, Ruppel, Jane, Boe, Marigold, Nakamura, Rin, Fu, Ling, Sumiyoshi, Teiko, Mokatrin, Ahmad, Shen, Xiaodong, Fine, Gregg, Chen, Daniel S, Hegde, Priti S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288453/ http://dx.doi.org/10.1186/2051-1426-2-S3-P136

Ejemplares similares

Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1
por: Kohrt, Holbrook, et al.
Publicado: (2013)

Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer
por: Xiao, Yuanyuan, et al.
Publicado: (2014)

P13. Intra-tumoral and surrogate immune responses in patients treated with the engineered anti-PD-L1 antibody (MPDL3280A)
por: Kowanetz, M, et al.
Publicado: (2014)

Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)
por: Powles, Thomas, et al.
Publicado: (2015)

S49. Clinical activity and development of biomarkers for an engineered anti PDL1 antibody MPDL3280A
por: Cha, E
Publicado: (2014)

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
por: Carbognin, Luisa, et al.
Publicado: (2015)

Draft genome sequencing of the sugarcane hybrid SP80-3280
por: Riaño-Pachón, Diego Mauricio, et al.
Publicado: (2017)

3280 Mycobacterium bovis Bacille-Calmette-Guérin infection aggravates atherosclerosis
por: Huaman, Moises, et al.
Publicado: (2019)

Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer
por: Li, Yijin, et al.
Publicado: (2021)

Unusually High Affinity of the PLK Inhibitors RO3280 and GSK461364 to HSA and Its Possible Pharmacokinetic Implications
por: Fernández-Sainz, Jesús, et al.
Publicado: (2023)

A BAC library of the SP80-3280 sugarcane variety (saccharum sp.) and its inferred microsynteny with the sorghum genome
por: Figueira, Thais Rezende e Silva, et al.
Publicado: (2012)

LBODP030 A Rare Case Of Partial Lipodystrophy From Mpdl (mandibular Hypoplasia, Deafness, Progeroid, Lipodystrophy Syndrome) Due To Pold1 Gene Mutation
por: Majumdar, Sujoyeeta, et al.
Publicado: (2022)

Molecular Targeting of the Oncoprotein PLK1 in Pediatric Acute Myeloid Leukemia: RO3280, a Novel PLK1 Inhibitor, Induces Apoptosis in Leukemia Cells
por: Wang, Na-Na, et al.
Publicado: (2015)

Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers
por: Schleifman, Erica B., et al.
Publicado: (2014)

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples
por: Wilson, Timothy R., et al.
Publicado: (2014)

Next Generation MUT-MAP, a High-Sensitivity High-Throughput Microfluidics Chip-Based Mutation Analysis Panel
por: Schleifman, Erica B., et al.
Publicado: (2014)

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
por: Vennapusa, Bharathi, et al.
Publicado: (2019)

Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody
por: Houot, Roch, et al.
Publicado: (2012)

Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy
por: Chester, Cariad, et al.
Publicado: (2015)

4-1BB agonism: adding the accelerator to cancer immunotherapy
por: Chester, Cariad, et al.
Publicado: (2016)

Immuno-thermal ablations – boosting the anticancer immune response
por: Slovak, Ryan, et al.
Publicado: (2017)

Manual simplificado de estilo /
por: Linton, Marigold
Publicado: (1989)

Manual simplificado de estilo : para la preparación y redacción de artículos de psicología, pedagogía, ciencias y literatura /
por: Linton, Marigold
Publicado: (1978)

A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial
por: Tan, Amabel CL, et al.
Publicado: (2015)

Immunotherapeutic approaches to ovarian cancer treatment
por: Chester, Cariad, et al.
Publicado: (2015)

C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients
por: Patil, Namrata S., et al.
Publicado: (2021)

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
por: Kowanetz, Marcin, et al.
Publicado: (2018)

TGFβ induces SIK to negatively regulate type I receptor kinase signaling
por: Kowanetz, Marcin, et al.
Publicado: (2008)

PMON192 Impact of Gender-Affirming Care Learning Module on Medical Students’ Knowledge and Self-Efficacy
por: Mokatrin, M×Raneem, et al.
Publicado: (2022)

Posterior parietal cortex estimates the relationship between object and body location during locomotion
por: Marigold, Daniel S, et al.
Publicado: (2017)

Learning from the Physical Consequences of Our Actions Improves Motor Memory
por: Bakkum, Amanda, et al.
Publicado: (2022)

A CD4/Foxp3/OX40 triple immunofluorescence assay determines association between T cell immune subsets and outcome in colorectal cancer
por: Ziai, James, et al.
Publicado: (2014)

Preexisting Antibodies to an F(ab′)(2) Antibody Therapeutic and Novel Method for Immunogenicity Assessment
por: Ruppel, Jane, et al.
Publicado: (2016)

Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment
por: Rajasekaran, Narendiran, et al.
Publicado: (2015)

Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer
por: Theelen, Willemijn S. M. E., et al.
Publicado: (2019)

No effect of triple-pulse TMS medial to intraparietal sulcus on online correction for target perturbations during goal-directed hand and foot reaches
por: Marigold, Daniel S., et al.
Publicado: (2019)

Subthreshold stochastic vestibular stimulation affects balance-challenged standing and walking
por: Piccolo, Chiara, et al.
Publicado: (2020)

Predicting CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy
por: Makkouk, Amani, et al.
Publicado: (2015)

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)
por: Carvajal-Hausdorf, Daniel, et al.
Publicado: (2019)

Profile of Immune Cells in Axillary Lymph Nodes Predicts Disease-Free Survival in Breast Cancer
por: Kohrt, Holbrook E, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_5rk8ikh0c5e577tgba3g1hbfr4